Immunophenotyping of acute myeloid leukaemia

Relevance of analysing different lineage-associated markers

Francesco Lo Coco, Daniela Pasqualetti, Manuela Lopez, Enrico Panzini, Alfonso Gentile, Roberto Latagliata, Bruno Monarca, Giulio De Rossi

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

The immunophenotype of 135 previously untreated patients with FAB defined acute myeloid leukaemia (AML) was studied at diagnosis. The panel of reagents included monoclonal antibodies (MoAb) recognising myeloid-associated determinants (CD11, CD13, CD14, CD33 and others) as well as MoAb directed towards lymphoid antigens (CD7, CD10, CD19) and TdT. The results indicate that CD13 and/or CD33 are consistently expressed in AML and only rarely in ALL blasts (131/135 +ve cases, versus 4/130 in ALL). Lymphoid antigen expression was rarely detected when CD10 and CD19 were investigated in AML (0.9% and 2% +ve cases, respectively), whereas significant positivities were found for TdT and CD7 (20% and 10% respectively). Concerning FAB subtypes, two new MoAb (LAM3 and LAM7) proved very useful in the specific recognition of AML with monocytic features. The phenotype CD13+ and/or CD33+, CD9+, HLA-DR- was found to be almost exclusive for M3 AML. The response to induction chemotherapy was analysed in CD7+ and in TdT+ patients. In the latter group a statistically significant lower response rate was found with respect to TdT-ve-AML patients.

Original languageEnglish
Pages (from-to)235-240
Number of pages6
JournalBlut
Volume58
Issue number5
DOIs
Publication statusPublished - May 1989

Fingerprint

Immunophenotyping
Acute Myeloid Leukemia
Monoclonal Antibodies
CD7 Antigens
Neprilysin
Acute Promyelocytic Leukemia
Induction Chemotherapy
HLA-DR Antigens
Phenotype
Antigens

Keywords

  • Acute myeloid leukaemia
  • Lymphoid-associated antigens
  • Monoclonal antibodies
  • Myeloid-associated antigens

ASJC Scopus subject areas

  • Hematology

Cite this

Coco, F. L., Pasqualetti, D., Lopez, M., Panzini, E., Gentile, A., Latagliata, R., ... De Rossi, G. (1989). Immunophenotyping of acute myeloid leukaemia: Relevance of analysing different lineage-associated markers. Blut, 58(5), 235-240. https://doi.org/10.1007/BF00320911

Immunophenotyping of acute myeloid leukaemia : Relevance of analysing different lineage-associated markers. / Coco, Francesco Lo; Pasqualetti, Daniela; Lopez, Manuela; Panzini, Enrico; Gentile, Alfonso; Latagliata, Roberto; Monarca, Bruno; De Rossi, Giulio.

In: Blut, Vol. 58, No. 5, 05.1989, p. 235-240.

Research output: Contribution to journalArticle

Coco, FL, Pasqualetti, D, Lopez, M, Panzini, E, Gentile, A, Latagliata, R, Monarca, B & De Rossi, G 1989, 'Immunophenotyping of acute myeloid leukaemia: Relevance of analysing different lineage-associated markers', Blut, vol. 58, no. 5, pp. 235-240. https://doi.org/10.1007/BF00320911
Coco, Francesco Lo ; Pasqualetti, Daniela ; Lopez, Manuela ; Panzini, Enrico ; Gentile, Alfonso ; Latagliata, Roberto ; Monarca, Bruno ; De Rossi, Giulio. / Immunophenotyping of acute myeloid leukaemia : Relevance of analysing different lineage-associated markers. In: Blut. 1989 ; Vol. 58, No. 5. pp. 235-240.
@article{5a0d6b000495420ebc9fafeba6fa0bc6,
title = "Immunophenotyping of acute myeloid leukaemia: Relevance of analysing different lineage-associated markers",
abstract = "The immunophenotype of 135 previously untreated patients with FAB defined acute myeloid leukaemia (AML) was studied at diagnosis. The panel of reagents included monoclonal antibodies (MoAb) recognising myeloid-associated determinants (CD11, CD13, CD14, CD33 and others) as well as MoAb directed towards lymphoid antigens (CD7, CD10, CD19) and TdT. The results indicate that CD13 and/or CD33 are consistently expressed in AML and only rarely in ALL blasts (131/135 +ve cases, versus 4/130 in ALL). Lymphoid antigen expression was rarely detected when CD10 and CD19 were investigated in AML (0.9{\%} and 2{\%} +ve cases, respectively), whereas significant positivities were found for TdT and CD7 (20{\%} and 10{\%} respectively). Concerning FAB subtypes, two new MoAb (LAM3 and LAM7) proved very useful in the specific recognition of AML with monocytic features. The phenotype CD13+ and/or CD33+, CD9+, HLA-DR- was found to be almost exclusive for M3 AML. The response to induction chemotherapy was analysed in CD7+ and in TdT+ patients. In the latter group a statistically significant lower response rate was found with respect to TdT-ve-AML patients.",
keywords = "Acute myeloid leukaemia, Lymphoid-associated antigens, Monoclonal antibodies, Myeloid-associated antigens",
author = "Coco, {Francesco Lo} and Daniela Pasqualetti and Manuela Lopez and Enrico Panzini and Alfonso Gentile and Roberto Latagliata and Bruno Monarca and {De Rossi}, Giulio",
year = "1989",
month = "5",
doi = "10.1007/BF00320911",
language = "English",
volume = "58",
pages = "235--240",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer Verlag",
number = "5",

}

TY - JOUR

T1 - Immunophenotyping of acute myeloid leukaemia

T2 - Relevance of analysing different lineage-associated markers

AU - Coco, Francesco Lo

AU - Pasqualetti, Daniela

AU - Lopez, Manuela

AU - Panzini, Enrico

AU - Gentile, Alfonso

AU - Latagliata, Roberto

AU - Monarca, Bruno

AU - De Rossi, Giulio

PY - 1989/5

Y1 - 1989/5

N2 - The immunophenotype of 135 previously untreated patients with FAB defined acute myeloid leukaemia (AML) was studied at diagnosis. The panel of reagents included monoclonal antibodies (MoAb) recognising myeloid-associated determinants (CD11, CD13, CD14, CD33 and others) as well as MoAb directed towards lymphoid antigens (CD7, CD10, CD19) and TdT. The results indicate that CD13 and/or CD33 are consistently expressed in AML and only rarely in ALL blasts (131/135 +ve cases, versus 4/130 in ALL). Lymphoid antigen expression was rarely detected when CD10 and CD19 were investigated in AML (0.9% and 2% +ve cases, respectively), whereas significant positivities were found for TdT and CD7 (20% and 10% respectively). Concerning FAB subtypes, two new MoAb (LAM3 and LAM7) proved very useful in the specific recognition of AML with monocytic features. The phenotype CD13+ and/or CD33+, CD9+, HLA-DR- was found to be almost exclusive for M3 AML. The response to induction chemotherapy was analysed in CD7+ and in TdT+ patients. In the latter group a statistically significant lower response rate was found with respect to TdT-ve-AML patients.

AB - The immunophenotype of 135 previously untreated patients with FAB defined acute myeloid leukaemia (AML) was studied at diagnosis. The panel of reagents included monoclonal antibodies (MoAb) recognising myeloid-associated determinants (CD11, CD13, CD14, CD33 and others) as well as MoAb directed towards lymphoid antigens (CD7, CD10, CD19) and TdT. The results indicate that CD13 and/or CD33 are consistently expressed in AML and only rarely in ALL blasts (131/135 +ve cases, versus 4/130 in ALL). Lymphoid antigen expression was rarely detected when CD10 and CD19 were investigated in AML (0.9% and 2% +ve cases, respectively), whereas significant positivities were found for TdT and CD7 (20% and 10% respectively). Concerning FAB subtypes, two new MoAb (LAM3 and LAM7) proved very useful in the specific recognition of AML with monocytic features. The phenotype CD13+ and/or CD33+, CD9+, HLA-DR- was found to be almost exclusive for M3 AML. The response to induction chemotherapy was analysed in CD7+ and in TdT+ patients. In the latter group a statistically significant lower response rate was found with respect to TdT-ve-AML patients.

KW - Acute myeloid leukaemia

KW - Lymphoid-associated antigens

KW - Monoclonal antibodies

KW - Myeloid-associated antigens

UR - http://www.scopus.com/inward/record.url?scp=0024357171&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024357171&partnerID=8YFLogxK

U2 - 10.1007/BF00320911

DO - 10.1007/BF00320911

M3 - Article

VL - 58

SP - 235

EP - 240

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

IS - 5

ER -